Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).

NCT00936234 is registered in ClinicalTrials.gov with Johann Wolfgang Goethe University Hospital as lead sponsor.

NCT NCT00936234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00936234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).
Lead sponsor
Johann Wolfgang Goethe University Hospital
Phase
Phase 2/3
Overall status
Withdrawn
Start date
July 31, 2009
Completion date
May 31, 2013
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sdf-1 is an important cytokine for neovascularization. cleavage of sdf-1 is reduced by dppiv inhibitors